Iyaku Joho Net Releases IBD Awareness Site Survey and Top 10 Treatment Drug Report for World IBD Day
Coinciding with World IBD Day on May 19, Iyaku Joho Net Co., Ltd. has released a research report on IBD (Inflammatory Bowel Disease) awareness websites operated by 20 pharmaceutical companies. The survey revealed that many sites provide content focusing on patients' daily life challenges, such as schooling and diet, in addition to disease information. Concurrently, the company published a "Top 10 Noteworthy IBD Drugs" report based on academic presentation data from the last five years. Both reports are available for free on the company's media platform, "Medinew."
📋 Article Processing Timeline
- 📰 Published: May 19, 2026 at 17:28
- 🔍 Collected: May 19, 2026 at 08:31
- 🤖 AI Analyzed: May 20, 2026 at 05:09 (20h 38m after Collected)
As the number of IBD patients in Japan continues to rise, pharmaceutical companies are using their owned media to disseminate a wide range of information, from disease understanding to daily life support. May 19 is annually recognized as World IBD Day, with global activities to promote understanding and awareness of the disease, originating from a world conference of IBD patient associations from 23 countries and the World Gastroenterology Organisation on May 19, 1990.
Iyaku Joho Net Co., Ltd. (CEO: Yugo Sasaki, Location: Akasaka, Minato-ku, Tokyo) has conducted a survey of IBD disease awareness sites run by pharmaceutical companies, based on the latest information from 2026. The study focused on five key content areas to summarize trends and design features of each site. Additionally, a trend analysis of IBD treatments based on academic conference presentation data has also been released. Both research findings are available for free on the company's media platform, Medinew.
## Survey of Pharmaceutical Companies' IBD Awareness Sites
Following up on its 2023 edition, the company re-surveyed IBD awareness sites operated by 20 pharmaceutical companies. The subjects were selected from the top 20 companies based on sales rankings from April 2024 to March 2025 (Source: IQVIA).
### Key Points from the Sites
IBD often develops in young people, leading to significant psychological burdens from difficulties in education and employment, and misunderstandings from others. Social barriers, such as restroom access when away from home, are also major challenges. Consequently, many sites were found to focus on life support, including education, employment, and diet, in addition to disease knowledge. Numerous patient support features were implemented, such as a 'consultation sheet for doctors' to encourage hospital visits, online games for learning about the disease in an engaging way, and searchable recipes and Q&As.
### Common Themes and Insights
The common thread among the surveyed sites was an effort to go beyond comprehensive disease explanations and address the specific, everyday problems patients face. By focusing on and delving into specific themes like dietary content, guides to local government support systems, and content on sensitive topics, sites were designed to be closely aligned with patients' real lives. For chronic diseases like IBD, merely 'delivering correct information' is insufficient; a perspective that offers an angle patients feel 'can answer my worries' and designs ways to ease their daily burdens is required.
The "Pharmaceutical Company Inflammatory Bowel Disease (IBD) Awareness Site Survey [May 2026 Edition]" can be downloaded for free from the following page: https://www.medinew.jp/downloads/research/owned-media-ibd-202605
## Top 10 Noteworthy IBD Drugs Report
Iyaku Joho Net provides an "Academic Conference Information Database" that aggregates data from academic conferences nationwide. This time, the company introduces a report that uses this database to analyze trends in IBD drugs over the past five years.
### Survey Overview
- **Analysis Method**: Calculated the number of presentations that included specific drug names in their titles from all presentations at three major IBD-related academic conferences held over the last five years.
- **Target Conferences**: The Japanese Society for Inflammatory Bowel Disease Annual Meeting (2020-2024), The Japanese Society of Gastroenterology General Meeting (2020-2024), and The Japanese Society of Gastroenterology Congress (2020-2024).
- **Target Drugs**: Included 5-ASA agents, steroids, calcineurin inhibitors, thiopurines, biologics, JAK inhibitors, PDE4 inhibitors, and S1P receptor modulators (extracted by generic name).
### Analysis Results
Among the top 10, the drug with the most presentations was "Ustekinumab," which was featured in 153 presentations.
Iyaku Joho Net Co., Ltd. (CEO: Yugo Sasaki, Location: Akasaka, Minato-ku, Tokyo) has conducted a survey of IBD disease awareness sites run by pharmaceutical companies, based on the latest information from 2026. The study focused on five key content areas to summarize trends and design features of each site. Additionally, a trend analysis of IBD treatments based on academic conference presentation data has also been released. Both research findings are available for free on the company's media platform, Medinew.
## Survey of Pharmaceutical Companies' IBD Awareness Sites
Following up on its 2023 edition, the company re-surveyed IBD awareness sites operated by 20 pharmaceutical companies. The subjects were selected from the top 20 companies based on sales rankings from April 2024 to March 2025 (Source: IQVIA).
### Key Points from the Sites
IBD often develops in young people, leading to significant psychological burdens from difficulties in education and employment, and misunderstandings from others. Social barriers, such as restroom access when away from home, are also major challenges. Consequently, many sites were found to focus on life support, including education, employment, and diet, in addition to disease knowledge. Numerous patient support features were implemented, such as a 'consultation sheet for doctors' to encourage hospital visits, online games for learning about the disease in an engaging way, and searchable recipes and Q&As.
### Common Themes and Insights
The common thread among the surveyed sites was an effort to go beyond comprehensive disease explanations and address the specific, everyday problems patients face. By focusing on and delving into specific themes like dietary content, guides to local government support systems, and content on sensitive topics, sites were designed to be closely aligned with patients' real lives. For chronic diseases like IBD, merely 'delivering correct information' is insufficient; a perspective that offers an angle patients feel 'can answer my worries' and designs ways to ease their daily burdens is required.
The "Pharmaceutical Company Inflammatory Bowel Disease (IBD) Awareness Site Survey [May 2026 Edition]" can be downloaded for free from the following page: https://www.medinew.jp/downloads/research/owned-media-ibd-202605
## Top 10 Noteworthy IBD Drugs Report
Iyaku Joho Net provides an "Academic Conference Information Database" that aggregates data from academic conferences nationwide. This time, the company introduces a report that uses this database to analyze trends in IBD drugs over the past five years.
### Survey Overview
- **Analysis Method**: Calculated the number of presentations that included specific drug names in their titles from all presentations at three major IBD-related academic conferences held over the last five years.
- **Target Conferences**: The Japanese Society for Inflammatory Bowel Disease Annual Meeting (2020-2024), The Japanese Society of Gastroenterology General Meeting (2020-2024), and The Japanese Society of Gastroenterology Congress (2020-2024).
- **Target Drugs**: Included 5-ASA agents, steroids, calcineurin inhibitors, thiopurines, biologics, JAK inhibitors, PDE4 inhibitors, and S1P receptor modulators (extracted by generic name).
### Analysis Results
Among the top 10, the drug with the most presentations was "Ustekinumab," which was featured in 153 presentations.